← Human Trials & Peer-Reviewed Studies
Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with different blood BNP levels
Plain-language guide to PMID 24593826 (2014): randomized controlled trial study of BNP (Nesiritide) in 58 patients.
Key Facts
- PMID
- 24593826
- Journal
- BMC cardiovascular disorders
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Pan HY et al. (6 authors)
- DOI
- 10.1186/1471-2261-14-31
What This Study Did, in Plain Language
What Was Tested
Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.
Recombinant human B-type natriuretic peptide (rhBNP) has been indicated for the treatment of acute decompensated heart failure (ADHF).
In this study, the researchers evaluated the effects of rhBNP on patients with different BNP levels.
Who Took Part
According to the abstract, 58 patients were involved.
By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.
In the high BNP group, 58 patients were randomized to subgroup rhBNP (n = 28) and subgroup dobutamine (n = 30).
In the extra-high BNP group, 47 patients were randomized to subgroup rhBNP (n = 24) and subgroup dobutamine (n = 23).
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Each group was then subdivided into rhBNP or dobutamine subgroups according to intravenous administration with either rhBNP or dobutamine for 24-72h.
The effects of rhBNP and dobutamine on patients in the high and extra-high BNP groups were compared.
What Was Measured
In this study, the researchers evaluated the effects of rhBNP on patients with different BNP levels.
PubMed files the paper under topics including Acute Disease, Administration, Intravenous, Blood Pressure, Cardiotonic Agents, China, Dobutamine and Heart Failure.
What This Means in Plain Language
The paper is a randomized study of BNP (Nesiritide) in 58 patients.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2014 (BMC cardiovascular disorders), a journal based in England.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.